BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS

FRANKLIN LAKES, N.J., Aug. 4, 2022

"Our BD2025 strategy continues to serve as our True North and has proven to be an effective, winning strategy as reflected in our continued strong performance, even amid a challenging macro environment," said Tom Polen, chairman, CEO and president of BD. "Through our talented team's focused execution and commitment to our purpose, we are advancing our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy, which are all contributing to profitable growth.  Looking forward, we expect continued momentum and remain well-positioned to drive long-term growth and value for all stakeholders."

Recent Business Highlights

BD continues to advance its innovation-driven growth strategy, tuck-in M&A, and ESG initiatives. 

• Acquired Parata Systems, entering high-growth pharmacy automation market segment by offering a comprehensive set of technologies across the care continuum, and furthering strategy to drive smart, connected care.

• Acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications, including connected pharmacy software to support the preparation of compounded medications.

• Launched BD COR™ System in U.S.  Fully automated, high-throughput infectious disease molecular diagnostic platform includes 510(k) cleared BD COR™ MX instrument that elevates standard of care for sexually transmitted infections.

• Obtained CE mark for COVID-19 and Influenza A/B combination test for BD COR™ MX.

• Launched CE marked BD MAX™ respiratory viral panel for COVID-19, Influenza A/B and Respiratory Syncytial Virus.

• Unveiled BD FACSDiscover™ S8 cell sorter at International Society for Advancement of Cytometry CYTO 2022 conference.  World's first spectral cell sorter with high-speed imaging technology that sorts cells based on visual characteristics.

• Issued 2021 ESG Report with notable progress toward 2030+ ESG commitments, addressing energy, water and waste reduction, environmental impact of product portfolio and supplier diversification.

• Named a "Noteworthy Company" for the third straight year in DiversityInc's annual ranking of the top U.S. companies for diversity.

• Recognized as a Best Place to Work for Disability Inclusion for the fourth consecutive year.  Perfect score on 2022 Disability Equality Index demonstrates progress in removing barriers and creating employment opportunities for people with disabilities.

Basis of Presentation— Continuing Operations

On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta Corp. ("Embecta"). The historical results of the Diabetes Care business that was contributed to Embecta in the spin-off are now accounted for as discontinued operations. Financial information presented in this release reflects BD's results on a continuing operations basis, which excludes Embecta. Prior periods have been recast to conform to this presentation.